膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human OX40 (Luc) HEK293 Reporter Cell was engineered to not only express NF-κB signaling response element, but also express the receptor full length human OX40 (Gene ID: 7293), which can drive luciferase expressing systems by OX40 ligand/agonist antibody stimulation. When stimulated with human OX40 ligand protein, the OX40 ligand/OX40 interaction drives NF-κB-mediated luminescence. Inhibition of OX40 ligand binding to OX40 by either anti-OX40 ligand or anti-OX40 antibodies results in a decrease in luminescence.
应用说明（Application）
• Screen for anti-human OX40 ligand or anti-human OX40 neutralizing antibody.
• Screen for ligands or agonist antibodies that can bind and activate OX40.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)
培养基（Culture Medium）
DMEM + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Expression analysis of human OX40 on Human OX40 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human OX40 (Luc) HEK293 Reporter Cell or negative control cell using biotinylated human OX40 ligand protein followed by staining with Streptavidin-PE.
Protocol
Application
Inhibition of human OX40 ligand protein-induced reporter activity by anti-human OX40 ligand neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human OX40 ligand protein with a final concentration of 0.02 μg/mL. The EC50 of anti-human OX40 ligand neutralizing antibody (Amlitelimab) was approximately 0.025 μg/mL.
Protocol
Signaling Bioassay
Response to human OX40 ligand protein (RLU).
The Human OX40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human OX40 ligand protein. The EC50 was approximately 0.0106 μg/mL.
Protocol
Response to human OX40 ligand protein (FOLD).
The Human OX40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human OX40 ligand protein. The max induction fold was approximately 12.04.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
